Literature DB >> 18245555

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.

Katie Twigger1, Laura Vidal, Christine L White, Johann S De Bono, Shreerang Bhide, Matt Coffey, Brad Thompson, Richard G Vile, Lucy Heinemann, Hardev S Pandha, Fiona Errington, Alan A Melcher, Kevin J Harrington.   

Abstract

PURPOSE: To test combination treatment schedules of reovirus and radiation in human and murine tumor cells in vitro and in vivo. EXPERIMENTAL
DESIGN: In vitro cytotoxicity and cell cycle effects of reovirus given alone and combined with radiotherapy were assessed by colorimetric, tissue culture infectious dose 50, and fluorescence-activated cell sorting-based assays. Interactions between the agents were evaluated using combination index analysis. The effect of different schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested in vitro and the combination was assessed in three tumor models in vivo.
RESULTS: Characterization of reovirus cytotoxicity in a panel of cell lines yielded a range of sensitivities. Combined reovirus and radiotherapy yielded statistically significantly increased cytotoxicity, particularly in cell lines with moderate susceptibility to reovirus alone. The enhanced cytotoxicity of the combination occurred independently of treatment sequence or schedule. Radiation did not affect viral replication and only reduced reoviral cytotoxicity after clinically irrelevant single doses (>50 Gy). Combination index analysis revealed synergy between radiation (3-10 Gy) and reovirus at multiplicities of infection between 0.001 and 1. Combination treatment significantly increased apoptosis in tumor cells relative to either single-agent treatment. In vivo studies using xenograft and syngeneic tumors showed enhanced activity of the combination relative to reovirus or radiation alone (P < 0.001).
CONCLUSIONS: Combining reovirus and radiotherapy synergistically enhances cytotoxicity in a variety of tumor cells in vitro and in vivo. These results offer strong support for translational clinical trials of reovirus plus radiotherapy that have been initiated in the clinic.

Entities:  

Mesh:

Year:  2008        PMID: 18245555     DOI: 10.1158/1078-0432.CCR-07-1400

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.

Authors:  A Black; D Morris
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

2.  Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.

Authors:  Chen Zhang; Bingfei Xu; Pian Liu
Journal:  Tumour Biol       Date:  2016-09-17

3.  BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Authors:  Victoria Roulstone; Malin Pedersen; Joan Kyula; David Mansfield; Aadil A Khan; Grainne McEntee; Michelle Wilkinson; Eleni Karapanagiotou; Matt Coffey; Richard Marais; Adel Jebar; Fiona Errington-Mais; Alan Melcher; Richard Vile; Hardev Pandha; Martin McLaughlin; Kevin J Harrington
Journal:  Mol Ther       Date:  2015-01-26       Impact factor: 11.454

4.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

Review 5.  Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

Authors:  T Pencavel; R Seth; A Hayes; A Melcher; H Pandha; R Vile; K J Harrington
Journal:  Gene Ther       Date:  2010-05-06       Impact factor: 5.250

6.  Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Authors:  Kevin J Harrington; Eleni M Karapanagiotou; Victoria Roulstone; Katie R Twigger; Christine L White; Laura Vidal; Debbie Beirne; Robin Prestwich; Kate Newbold; Merina Ahmed; Khin Thway; Christopher M Nutting; Matt Coffey; Dean Harris; Richard G Vile; Hardev S Pandha; Johann S Debono; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

Review 7.  Reovirus: a targeted therapeutic--progress and potential.

Authors:  Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Authors:  Shizuko Sei; Jodie K Mussio; Quan-en Yang; Kunio Nagashima; Ralph E Parchment; Matthew C Coffey; Robert H Shoemaker; Joseph E Tomaszewski
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

9.  Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.

Authors:  Karsten Geletneky; Andreas D Hartkopf; Robert Krempien; Jean Rommelaere; Joerg R Schlehofer
Journal:  J Biomed Biotechnol       Date:  2010-03-07

Review 10.  Oncolytic viruses: a novel form of immunotherapy.

Authors:  Robin J Prestwich; Kevin J Harrington; Hardev S Pandha; Richard G Vile; Alan A Melcher; Fiona Errington
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.